Thyrocare's Q1FY26 Results - Thyrocare Technologies Limited reports revenue of INR 193.03 Cr in Q1FY26 with a growth of 23% YoY​

Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare” NSE: THYROCARE,
BSE: 539871), a leading healthcare diagnostics company, announces their results for the quarter ended June 30, 2025.

Key highlights for Q1FY26:

·     Consolidated revenue saw a YoY increase of 23%, driven by a 25% growth in Pathology and an 6% growth in Radiology.

·     Pathology Business - Franchise revenue grew by 20% YoY, while partnership revenue surged by 36% YoY.

·     Total test volume reached 46.9 million in Q1FY26, reflecting a 15% YoY increase.

·     Consolidated Gross Margin stood at 71%, with reported EBITDA margin at 30%.

·     Consolidated reported EBITDA grew by 37% YoY, while PAT saw a significant YoY increase of 62%.

·     Opened New Labs in Bhagalpur, Kashmir and Roorkee.

Thyrocare Technologies Limited (NSE: THYROCARE, BSE: 539871) is India's first and foremost advanced fully automated laboratory chain with strong presence PAN India. Thyrocare focuses on providing quality and affordable diagnostic services to laboratories and hospitals. Many laboratories and hospital brands all over India use the comprehensive test profile menu offered by Thyrocare.

Thyrocare has an extensive network of laboratories across PAN India. Thyrocare has a Quarterly active franchise count of 9,500+ and processed 46.9mn+ diagnostic and screening investigations in Q1FY26.

Thyrocare is one of the first Indian diagnostic laboratories to obtain internationally renowned quality accreditations including ISO 9001-2000 rating as early as 2001, which was upgraded to ISO 9001:2015 and National Accreditation Board for Testing and Calibration Laboratories (NABL) and College of American Pathologists (CAP) accreditations in 2005.